Regeneron Provides Update on Phase 3 Trial of Fianlimab (LAG-3 Inhibitor) Combination in First-Line Unresectable or Metastatic Melanoma
May 15, 2026 20:19 ET | Source: Regeneron Pharmaceuticals, Inc. The trial…
GLG Provides Expert Insights on Bloomberg’s ASKB
GLG and Bloomberg Terminal® clients can now access the premium research provider's…
Sankaty Jet Capital Provides $68 Million Debt Facility to Wheels Up
Sankaty Jet Capital, a wholly owned subsidiary of AIP Capital, has committed…
ZyVersa Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
ZyVersa is advancing a highly differentiated pipeline focusing on inflammatory and renal…
uniQure Announces First Quarter 2026 Financial Results and Provides Recent Company Updates
~ Advancing FDA interactions on AMT-130 for Huntington’s disease; Type B meeting…
Nicox Provides Full Year 2025 Financial Results and Corporate Update
April 30, 2026 01:30 ET | Source: NICOX SA Press Release Nicox…
CORRECTION — Quoin Pharmaceuticals Provides Clinical and Regulatory Update for QRX009 Topical Rapamycin Development Programs
Company Planning Multi-Pronged Approach for QRX009 Including Several Investigator Led Clinical Studies…
Oncotelic Therapeutics Provides Corporate Update on Partnership Strategy
AGOURA HILLS, Calif., April 24, 2026 (GLOBE NEWSWIRE) -- Oncotelic Therapeutics, Inc.…
Connect Biopharma Reports 2025 Full-Year Financial Results and Provides Business Update
– Released positive topline data from Phase 1 study of IV rademikibart…
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl Cyclases as Promising Targets in DKD at World Congress of Nephrology
Vivoryon Therapeutics N.V. Provides Update on Growing Body of Evidence Validating Glutaminyl…
